Abstract |
We developed a clinically compatible protocol for the production of engineered tissue for grafting into the injured spinal cord. We used autologous tissue derived from pre-ligated peripheral nerves, which avoids supply, immunocompatibility and ethical hinderances, combined with non-viral transfection, which is a versatile and non-immunogenic gene transfer method. In-vitro transfection of glial cells or primary tissue from pre-ligated rat peripheral nerve with the neurotrophic gene brain-derived neurotrophic factor significantly enhanced its expression, when quantified or labelled by immunofluorescence. Engineered tissue expressed brain-derived neurotrophic factor after being grafted into the spinal cord of rats that had received spinal contusion injury 3 weeks before. Anatomical and functional assays of repair, conducted on a small cohort, showed that the treatment may promote axonal regeneration and improve motor performance.
|
Authors | Rogan B Tinsley, Shu-Hua Zhang, Shi-Qing Feng, Robert A Rush, Ian A Ferguson |
Journal | Neuroreport
(Neuroreport)
Vol. 17
Issue 3
Pg. 261-5
(Feb 27 2006)
ISSN: 0959-4965 [Print] England |
PMID | 16462594
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Brain-Derived Neurotrophic Factor
- Receptors, Growth Factor
- Polyethyleneimine
- beta-Galactosidase
|
Topics |
- Analysis of Variance
- Animals
- Brain-Derived Neurotrophic Factor
(biosynthesis, genetics, therapeutic use)
- Cells, Cultured
- Disease Models, Animal
- Enzyme-Linked Immunosorbent Assay
(methods)
- Female
- Genetic Therapy
(methods)
- Immunohistochemistry
(methods)
- Polyethyleneimine
(pharmacology)
- Rats
- Receptors, Growth Factor
(metabolism)
- Spinal Cord Injuries
(therapy)
- Sural Nerve
(physiology, transplantation)
- Transfection
(methods)
- Transplantation, Autologous
(methods)
- beta-Galactosidase
(metabolism)
|